Phibro Animal Health (PAHC) Non-Current Assets (2013 - 2026)
Phibro Animal Health's (PAHC) quarterly Non-Current Assets came in at $551.0 million in Q1 2026, up 1.81% year-on-year from $541.2 million in Q1 2025, and up 1.41% quarter-over-quarter from $543.4 million in Q4 2025.
Phibro Animal Health (PAHC) Non-Current Assets (2013 - 2026) Analysis & Trends
Phibro Animal Health's Non-Current Assets history runs 14 years deep, the most recent figure standing at $551.0 million for Q1 2026.
- On a quarterly basis, Non-Current Assets rose 1.81% year-over-year to $551.0 million in Q1 2026; TTM through Mar 2026 was $2.2 billion, a 18.15% increase from a year earlier, with the FY2025 full-year figure at $550.3 million, up 44.36% from the prior year.
- Non-Current Assets improved to $551.0 million in Q1 2026 per PAHC's latest filing, from $543.4 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $551.0 million in Q1 2026 and bottomed at $365.5 million in Q2 2022.
- The 5-year median for Non-Current Assets is $385.7 million (2023), against an average of $438.8 million.
- Across the five-year window, Non-Current Assets fell 1.16% in 2024 and soared 44.36% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $380.1 million in 2022, then rose by 1.57% to $386.1 million in 2023, then soared by 39.69% to $539.4 million in 2024, then rose by 0.74% to $543.4 million in 2025, then rose by 1.41% to $551.0 million in 2026.
- Per Business Quant, the three latest PAHC Non-Current Assets figures stand at $551.0 million (Q1 2026), $543.4 million (Q4 2025), and $549.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Phibro Animal Health | 1.38 Bn | 1.30 Bn | 125.68 Mn | 551.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 551.05 Mn |
| Dec 31, 2025 | 543.37 Mn |
| Sep 30, 2025 | 549.73 Mn |
| Jun 30, 2025 | 550.29 Mn |
| Mar 31, 2025 | 541.24 Mn |
| Dec 31, 2024 | 539.36 Mn |
| Sep 30, 2024 | 395.52 Mn |
| Jun 30, 2024 | 381.19 Mn |
| Mar 31, 2024 | 381.86 Mn |
| Dec 31, 2023 | 386.12 Mn |
| Sep 30, 2023 | 380.10 Mn |
| Jun 30, 2023 | 385.67 Mn |
| Mar 31, 2023 | 379.95 Mn |
| Dec 31, 2022 | 380.14 Mn |
| Sep 30, 2022 | 378.30 Mn |
| Jun 30, 2022 | 365.47 Mn |
| Mar 31, 2022 | 369.70 Mn |
| Dec 31, 2021 | 340.35 Mn |
| Sep 30, 2021 | 337.41 Mn |
| Jun 30, 2021 | 342.42 Mn |